Heron Therapeutics Inc (NASDAQ:HRTX) shares traded 4.88% higher at $3.01 on Wall Street last session.
HRTX stock price is now 10.73% away from the 50-day moving average and 64.30% away from the 200-day moving average. The market capitalization of the company currently stands at $453.43M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $6, CapitalOne recently initiated with Overweight rating for Heron Therapeutics Inc (NASDAQ: HRTX). On March 13, 2024, Needham reiterated its ‘Buy’ rating on the stock by increasing its target price from $4 to quote $5, while ‘Guggenheim’ rates the stock as ‘Buy’
In other news, Forbes William P, EVP, Chief Development Officer bought 25,000 shares of the company’s stock on Nov 17 ’23. The stock was bought for $27,250 at an average price of $1.09. Upon completion of the transaction, the EVP, Chief Development Officer now directly owns 79,000 shares in the company, valued at $0.24 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 16 ’23, Chief Executive Officer Collard Craig A bought 150,000 shares of the business’s stock. A total of $137,970 was incurred on buying the stock at an average price of $0.92. This leaves the insider owning 186,496 shares of the company worth $0.56 million. A total of 5.10% of the company’s stock is owned by insiders.
During the past 12 months, Heron Therapeutics Inc has had a low of $0.50 and a high of $3.22.
According to the Biotechnology Company, earnings per share came in at -0.35, missing analysts’ expectations of -0.23 by -0.12. This compares to -$0.27 EPS in the same period last year. The net profit margin was -61.28% and return on equity was -2408.88% for HRTX. The company reported revenue of $34.67 million for the quarter, compared to $29.61 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17.07 percent. For the current quarter, analysts expect HRTX to generate $34.62M in revenue.
Heron Therapeutics Inc(HRTX) Company Profile
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
